Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

(“Vertex” or the “Company”), a global provider of tax technology solutions, has been named a Leader in three IDC MarketScape reports: IDC MarketScape: Worldwide SaaS and Cloud-Enabled SaaS ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex, Inc., a leading provider of tax technology solutions, has been recognized as a Leader in three recent IDC MarketScape reports assessing SaaS and cloud-enabled tax automation software for ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

The VERTEX 80/80v optics design allows PEAK flexibility and PEAK instrument performance at the same time. The unique Bruker Optics DigiTect ™ technology ensures PEAK signal-to-noise ratio ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...